The effects of medications used for the management of dyslipidemia on postprandial lipemia.
Postprandial lipemia has emerged as an independent risk factor for coronary artery disease. In this systematic review we examined the effect of the medications used for the management of dyslipidemia on postprandial lipemia. Statins, beyond their effects on fasting lipid levels, reduce also postprandial lipemia mainly by inhibiting the production of apoB containing lipoproteins from the liver and thus increasing the clearance of triglyceride-rich lipoproteins of either liver or intestinal origin. Fibrates decrease fasting triglyceride and increase high density lipoprotein cholesterol levels. Besides, fibrates are particularly potent drugs in the reduction of postprandial lipemia; they decrease the production or triglyceride-rich lipoproteins and increase their clearance by enhancing the activity of lipoprotein lipase.
Tentolouris
N
N
1st Department of Propaedeutic Medicine, Athens University Medical School, Athens, Greece. ntentol@med.uoa.gr
Eleftheriadou
I
I
Katsilambros
N
N
D001055:Apolipoproteins B / Q000037:antagonists & inhibitors; D053480:Cholesterol Ester Transfer Proteins / Q000378:metabolism; D002914:Chylomicrons / Q000378:metabolism; D002995:Clofibric Acid / Q000627:therapeutic use; D003324:Coronary Artery Disease / Q000628:therapy; D050171:Dyslipidemias / Q000188:drug therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D019518:Postprandial Period; D014280:Triglycerides / Q000378:metabolism
D001055:Apolipoproteins B; D053480:Cholesterol Ester Transfer Proteins; D002914:Chylomicrons; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D014280:Triglycerides; D002995:Clofibric Acid